India, April 29 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), on Wednesday said it has agreed to acquire Emalex Biosciences for up to $900 million.
The acquisition adds Emalex's lead asset, ecopipam, to Teva's portfolio, which is proposed for the treatment of pediatric Tourette syndrome. A Phase 3 study had met its primary endpoint, and an NDA submission is expected in the second half of 2026.
Under the agreement, Emalex shareholders will receive $700 million in cash upfront and may receive up to an additional $200 million in commercial milestone payments, along with sales-based royalties.
Teva plans to fund the upfront payment using cash on hand and said it aims to mitigate the near-term margin...